生命科学资讯

How Mirum is Advancing Rare Disease Care Through Strategic M&A

Novo’s CagriSema tops semaglutide in ph. 3 diabetes study

GSK gives back rights to Wave's genetic disease RNA editor

Thermo Fisher trims Massachusetts headcount with Franklin site closure

GSK plans to lay off up to 350 R&D workers across US, UK

Early-stage investor Santé Ventures gins up $330M to spread across biotech, medtech and digital health

Roche's return to RNA continues with $1.7B deal for Sanegene program

Optellum tapped by NHS for AI-powered lung cancer diagnostic initiative

China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug

Daiichi stops internal development of next-wave ADC as key Datroway readout delayed again

Sanofi's troubled GCS inhibitor fails phase 3 Fabry trial but scores in Gaucher disease

AstraZeneca study finds 22 genes tied to chronic disease risk after Epstein-Barr infection

CRO Sygnature Discovery plans to send 60 UK staffers packing

Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’

Chutes & Ladders—Cardiff churns C-suite to advance cancer candidate

Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program

Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech

Moderna's latest CMO steps down after barely a year

Moderna offloads late-stage rare disease drug to Recordati for $50M upfront

AstraZeneca returns to China's CSPC for $18.5B obesity deal